Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

Intravesical administration of traditional drugs has been tried as an alternative to conventional oral administration for the unstable bladder. This route of instillation offers the possibility to ...

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

including Ferring's intravesical gene therapy Adstiladrin (nadofaragene firadenovec) and ImmunityBio's IL-15 receptor agonist Anktiva (nogapendekin alfa inbakicep), which both launched in the US ...

Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 ...